Pathophysiology may help ID rare, early form of Alzheimer's

July 12, 2012 in Alzheimer's disease & dementia

Pathophysiology may help ID rare, early form of alzheimer's

In dominantly inherited Alzheimer's disease, clinical and biomarker changes occur decades before the expected onset of disease symptoms, according to a study published online July 11 in the New England Journal of Medicine.

(HealthDay) -- In dominantly inherited Alzheimer's disease, clinical and biomarker changes occur decades before the expected onset of disease symptoms, according to a study published online July 11 in the New England Journal of Medicine.

Randall J. Bateman, M.D., from the Washington University School of Medicine in St. Louis, and colleagues conducted a prospective longitudinal study, analyzing data from 128 participants to examine the order and magnitude of pathologic processes. The participants underwent baseline clinical and cognitive assessments, brain imaging, and (CSF) and blood tests. The participant age at baseline and parental age at the onset of Alzheimer's symptoms were used to estimate the years to .

Twenty-five years before expected symptom onset, the researchers found that the concentrations of amyloid-beta (Aβ)42 in the CSF appeared to decline. Fifteen years before expected symptom onset, Aβ deposition in the brain was detected, as were increased concentrations of tau protein in the CSF and an increase in brain atrophy. Ten years before expected symptom onset, cerebral hypometabolism and impaired episodic memory were observed. Five years before expected symptom onset, global cognitive impairment was detected, as measured by the Mini-Mental State Examination and the Clinical Dementia Rating scale. The diagnostic criteria for dementia were met an average of three years after expected onset of symptoms.

"Autosomal dominant Alzheimer's disease was associated with a series of pathophysiological changes over decades in CSF biochemical markers of Alzheimer's disease, brain amyloid deposition, and brain metabolism as well as progressive cognitive impairment," the authors write.

Several authors disclosed financial ties to pharmaceutical, biotechnology, and diagnostic companies.

More information: Abstract
Full Text

Journal reference: New England Journal of Medicine search and more info website

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Study identifies new approach to improving treatment for MS and other conditions

(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...

Alzheimer's disease & dementia created May 17, 2013 | popularity 5 / 5 (2) | comments 0 | with audio podcast

Nonmelanoma skin cancer tied to lower Alzheimer's risk

(HealthDay)—Older individuals with nonmelanoma skin cancer (NMSC) seem to have a significantly reduced risk of developing Alzheimer's disease (AD), according to a study published online May 15 in Neurology.

Alzheimer's disease & dementia created May 16, 2013 | popularity 5 / 5 (1) | comments 0

Skin cancer may be linked to lower risk of Alzheimer's disease

People who have skin cancer may be less likely to develop Alzheimer's disease, according to new research published in the May 15, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. The li ...

Alzheimer's disease & dementia created May 15, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

Alzheimer's markers predict start of mental decline

(Medical Xpress)—Scientists at Washington University School of Medicine in St. Louis have helped identify many of the biomarkers for Alzheimer's disease that could potentially predict which patients will develop the disorder ...

Alzheimer's disease & dementia created May 14, 2013 | popularity 3 / 5 (1) | comments 0 | with audio podcast

Scientists develop drug that slows Alzheimer's in mice

A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment. The findings, ...

Alzheimer's disease & dementia created May 13, 2013 | popularity 4.2 / 5 (5) | comments 0 | with audio podcast


'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

Consuming coffee linked to lower risk of detrimental liver disease, study finds

Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...

Ketamine shows significant therapeutic benefit in people with treatment-resistant depression

Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...

Research examines new methods for managing digestive health

Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.

New smartphone application improves colonoscopy preparation

The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...

New research identifies risks, interventions for children's GI health

An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).